Home › Funds › Elmind Capital, LP › CTMX
Elmind Capital, LP position in CTMX
CYTOMX THERAPEUTICS INC. · Health Care
Elmind Capital, LP reported holding 4,550,000 shares of CTMX (CYTOMX THERAPEUTICS INC.) in its Q2 2026 13F filing — a position valued at US$17.1M, representing 4.29% of its reported portfolio and ranking #9 among its reported holdings. Elmind Capital, LP has disclosed CTMX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's CTMX position evolved
Elmind Capital, LP first disclosed a stake in CTMX in Q4 2025 at 700,000 shares (US$3.0M). The position peaked in Q1 2026 at 4,550,000 shares, worth US$21.4M. Across 3 filings, Elmind Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 4,550,000 shares valued at US$17.1M. Notable position changes include a 550% increase in Q1 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 700.00K | $2.98M | New |
| Q1 2026 | 4.55M | $21.39M | Add |
| Q2 2026 | 4.55M | $17.06M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CTMX and 13F data
CTMX (CYTOMX THERAPEUTICS INC.) is a Health Care company. 45 other funds we track also report a position in CTMX — the largest reported positions include Kynam Capital Management, LP (US$81.4M), PERCEPTIVE ADVISORS LLC (US$39.1M), Venrock Adviser, LLC (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CTMX
- Kynam Capital Management, LP 21.70M sh · $81.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.44M sh · $39.15M · Q2 2026
- Venrock Adviser, LLC 4.98M sh · $18.68M · Q2 2026
- Nextech Invest Ltd. 4.45M sh · $16.69M · Q2 2026
- Eversept Partners, LP 3.56M sh · $13.34M · Q2 2026
- ADAR1 Capital Management, LLC 3.37M sh · $12.62M · Q2 2026
- Seven Fleet Capital Management LP 1.09M sh · $4.07M · Q2 2026
- Ally Bridge Group (NY) LLC 775.00K sh · $2.91M · Q2 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held CTMX?
Elmind Capital, LP has disclosed CTMX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in CTMX?
As of Q2 2026, Elmind Capital, LP holds 4.55M shares of CTMX (CYTOMX THERAPEUTICS INC.), valued at $17.06M, representing 4.29% of its reported portfolio and ranking #9.
Has Elmind Capital, LP been buying or selling CTMX?
In the latest 13F filing (Q2 2026), Elmind Capital, LP held unchanged its position in CTMX. The position peaked in Q1 2026 at 4.55M shares.
Which other funds hold CTMX?
Other major institutional holders of CTMX include Kynam Capital Management, LP, PERCEPTIVE ADVISORS LLC, Venrock Adviser, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.